Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2029

Conditions
Breast Cancer FemaleHormone Receptor Positive Tumor
Interventions
DRUG

Tamoxifen Citrate

current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test

Trial Locations (1)

V5Z4E6

BC Cancer, Vancouver

Sponsors
All Listed Sponsors
collaborator

Canadian Cancer Society (CCS)

OTHER

collaborator

NanoString Technologies, Inc.

INDUSTRY

lead

British Columbia Cancer Agency

OTHER

NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer | Biotech Hunter | Biotech Hunter